Weekly Oxaliplatin, High-Dose Folinic Acid and 24h-5-fluorouracil (FUFOX) as Salvage Therapy in Metastatic Colorectal Cancer Patients Pretreated with Irinotecan and Folinic Acid/5-Fluorouracil Regimens

Zusammenfassung

Irinotecan (CPT-11), Oxaliplatin (OXA) und Kombinationen von Folinsäure (FA) und 5-Fluorouracil (5-FU) sind aktive Substanzen in der Erst- und Zweittherapie des metastasierten kolorektalen Karzinoms. Bisher ist jedoch unklar, ob und von welcher Sequenz diese Patienten in der Zweit- und Dritttherapie am ehesten profitieren. Nach Erst- und Zweittherapie mit CPT-11 gibt es gegenwärtig keine evidenzbasierten Daten zu Folgeprotokollen. Daher untersuchten wir retrospektiv Nebenwirkungen, Ansprechrate und Gesamtüberleben von Patienten, die ambulant mit der wöchentlichen Kombination von Oxaliplatin und hochdosierter Folinsäure mit 5-Fluorouracil (FUFOX) nach zwei unterschiedlichen CPT-11-haltigen Protokollen behandelt wurden.

Patienten: Von Oktober 1999 bis Mai 2001 wurden 20 Patienten (Median 62; 48-74 Jahre) eingeschlossen, die unter Vortherapie progredient waren. 7 Patienten erhielten initial CPT-11/Bolus-FA/5-FU (gemäß Saltz, Gruppe A), 13 Patienten initial FA/5-FU und danach CPT-11 Mono (Gruppe B). Das Protokoll war OXA (60 mg/m²), FA (500 mg/m²), 5-FU (2,6 g/m², 24h-Port-Infusion), Tag 1, 8, 15, 22, danach 2 Wochen Pause.

Ergebnisse: 252 Gaben FUFOX wurden ambulant verabreicht (1203 mg Dosis OXA/Pat). Bei 10 Patienten traten Toxizitäten NCI-CTC-Grad 3 auf: 4 × Diarrhö, 5 × Mukositis, 2 × Übelkeit/Erbrechen, je 1 × Anämie, Thrombopenie, Leukopenie bzw. Hand-Fuß-Syndrom. Drei Patienten zeigten minimale Remission, 11 Patienten stabilen Krankheitsverlauf. Das mediane Überleben ab Beginn von FUFOX war 33 (i. r. 5-65), die mediane progressionsfreie Zeit lag bei 16 (0-39) Wochen. Das Gesamtüberleben ab Beginn der palliativen Ersttherapie war 99 (44-200) Wochen.

Schlussfolgerungen: FUFOX erreichte bei akzeptablem Toxizitätsprofil eine Tumorkontrolle in 70 % und bei individuellen Patienten eine Lebensverlängerung. Nach FA/5-FU- und CPT-11-Vorbehandlung ist FUFOX eine wirksame Therapieoption des metastasierten kolorektalen Karzinoms.

Abstract

Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid (FA) modulated 5-fluorouracil (5-FU) regimens are active as first- and second-line chemotherapy of metastatic colorectal cancer. However, the best palliative sequence of these substances is still unclear. After CPT-11 containing regimens the optimal salvage protocol has not yet been defined. Here, we retrospectively analysed the weekly ambulant combination of OXA with continuous FA/5-FU (FUFOX) after two different CPT-11 containing chemotherapeutic regimens.

Patients: During October 1999 and May 2001, 20 patients (median 62; 48-74 years) were included who had disease progression after CPT-11/bolus FA/5-FU (Saltz; 7 patients, group A) or after FA/5-FU followed by CPT-11 alone (13 patients, group B). OXA (60 mg/m²) was given for 2 hours prior to FA (500 mg/m²) as 2 h-infusion and continuous 5-FU (2.600 mg/m²) for 24 h-infusion on day 1, 8, 15 and 22 (repeated after week 6).

Results: FUFOX was administered 252 times. About 1,203 mg OXA per patient was given. Toxicities NCI-CTC grade 3 were observed in 10 patients: diarrhoea (4), mucositis (5), nausea/vomiting (2), anaemia (1), leucopenia (1), thrombopenia (1) and hand-foot-syndrome (1). 3 patients showed minor remissions, 11 patients stable disease. The median time to progression was 16 (0-39) weeks. The median survival from start of FUFOX and from start of any palliative therapy was 33 (5-65) and 99 (44-200) weeks for all patients, respectively.

Conclusions: FUFOX was efficient for additional tumour control in 70 % of patients pretreated with CPT-11/5-FU based regimens. Sequential palliative treatment can lead to prolonged survival.

Metastasierendes kolorektales Karzinom - Chemotherapie - 5-Fluorouraciloxaliplatin - Irinotecan

Metastatic colorectal carcinoma - chemotherapy - 5-fluorouracil - oxaliplatin - irinotecan

References

• 1 Rougier P R, Bugat R, Douillard J Y. et al . Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil based chemotherapy.  J Clin Oncol. 1997;  15 251-260
• 2 Saltz L B, Cox J V, Blanke C. et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2000;  343 905-914
• 3 Douillard J Y, Cunningham D, Roth A D. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial.  Lancet. 2000;  355 1041-1047
• 4 Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer.  Semin Oncol. 1998;  25 32-39
• 5 Giacchetti S, Perpoint B, Zidani R. et al . Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2000;  18 136-147
• 6 De Gramont A, Figer A, Seymour M. et al . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 2938-2294
• 7 Cunningham D, Pyrhönen S, James R D. et al . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.  Lancet. 1998;  352 1413-1418
• 8 Rougier P, Van Cutsem E, Bajetta E. et al . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.  Lancet. 1998;  352 1407-1412
• 9 De Gramont A, Vignoud J, Tournigand C. et al . Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.  Eur J Cancer. 1997;  33 214-219
• 10 André T, Louvet C, Raymond E. et al . Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.  Ann Oncol. 1998;  9 1251-1253
• 11 André T, Bensmaine M A, Louvet C. et al . Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regime.  J Clin Oncol. 1999;  17 3560-3568
• 12 Maindrault-Goebel F, Louvet C, Andre T. et al . Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.  Eur J Cancer. 1999;  35 1338-1342
• 13 Gramont, Gastiaburu J, Tournigand C. et al . Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer.  Proc Am Soc Clin Oncol. 1994;  13 220a
• 14 Maindrault-Goebel F, de Gramont A, Louvet C. et al . High-dose oxaliplatin with the simplified 48 h bimonthly leucovorin (LV) and 5-fluorouracil (5-FU) regimen in pretreated metastatic colorectal cancer (FOLFOX).  Proc Am Soc Clin Oncol. 1999;  18 A1017
• 15 Janinis J, Papakostas K, Samelis G. et al . Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.  Ann Oncol. 2000;  11 163-167
• 16 Kouroussis C, Mavroudis D, Giannakakis T. et al . Biweekly oxaliplatin (L-OHP) with high-dose leucovorin (LV) and 5-fluorouracil (5-FU) 48-hour continuous infusion in pretreated patients with advanced colorectal cancer (CRC).  Proc Am Soc Clin Oncol. 1999;  18 A1111
• 17 Meyer V, Delva R, Gamelin E. et al . Oxaliplatin (L-OHP) and fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC).  Eur J Cancer. 1997;  33 A746
• 18 Gerard B, Bleiberg H, Michel J. et al . Oxaliplatin combined to 5-fluorouracil and folinic acid (FA/5-FU) as second or third line treatment in patients with advanced colorectal cancer (CRC).  Proc Am Soc Clin Oncol. 1997;  16 A1025
• 19 Martoni A. Oxaliplatin (OHP) and protracted 5-fluorouracil (5-FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients: a phase II study.  Proc Am Soc Clin Oncol. 2000;  19 A1172
• 20 Zaniboni A, Merrigi F, Aitini E. et al . Oxaliplatin (OX) and 5-fluorouracil (5-FU) and leucovorin (LV) as salvage treatment for advanced colorectal cancer (ACC).  Proc Am Soc Clin Oncol. 2000;  19 A1195
• 21 Brienza S, Bensmaine M A, Soulie P. et al . Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.  Ann Oncol. 1999;  10 1311-1316
• 22 Van Cutsem E, Bajetta E, Niederle N. et al . A phase III multicenter randomised trial comparing CPT-11 to infusional 5FU regimen in patients (Pts) with advanced colorectal cancer (ACRC) after 5FU failure.  Proc Am Soc Clin Oncol. 1998;  17 256A
• 23 Lokich J J, Ahlgren J D, Gullo J J. et al . A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study.  J Clin Oncol. 1989;  7 425-432
• 24 Ardalan B, Chua L, Tian E. et al . A Phase II Study of weekly 24-hour infusion with high-dose fluoruracil with leucovorin in colorectal carcinoma.  J Clin Oncol. 1991;  9 625-630
• 25 Weh H J, Wilke H J, Dierlamm J. et al . Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma.  Ann Oncol. 1994;  5 233-237
• 26 Meta-analysis Group in Cancer . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.  J Clin Oncol. 1998;  16 301
• 27 De Gramont A, Bosset J F, Milan C. et al . Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study.  J Clin Oncol. 1997;  15 808-815
• 28 Kallen K J, Hofmann M A, Timm A. et al . Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.  Z Gastroenterol. 2000;  38 153-157
• 29 Tournigand C, Louvet C, Quinaux E. et al . FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study.  Proc Am Soc Clin Oncol. 2001;  20 494A
• 30 Kouroussis C, Souglakos J, Giannakanis T. et al . Biweekly oxaliplatin (L-OHP) with high-dose leucovorin and 5-fluorouracil (5-FU) in irinotecan pretreated patients with advanced colorectal cancer (ACC).  Proc Am Soc Clin Oncol. 2000;  19 1203A
• 31 Levi F, Perpoint B, Garufi C. et al . Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circardian rhythm modulated rate.  Eur J Cancer. 1993;  29 1280-1284
• 32 Diaz-Rubio E, Sastre J, Zaniboni A. et al . Oxaliplatin as a single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study.  Ann Oncol. 1998;  9 105-108
• 33 Machover D, Diaz-Rubio, de Gramont A. et al . Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.  Ann Oncol. 1996;  7 95-98
• 34 Buechele T, Kroening H, Reichardt P. et al . Bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo Clinic) versus weekly high-dose 24-hour 5-FU infusion + FA + Oxaliplatin (L-OHP) in advanced colorectal cancer (CRC). A randomised phase III study.  Onkologie. 2000;  3 9-36
• 35 Pitot H C, Wender D B, O’Connell M J. et al . Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.  J Clin Oncol. 1997;  15 2910-2919
• 36 Poon M A, O’Connell M J, Wieand H S. et al . Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.  J Clin Oncol. 1991;  9 1967-1972
• 37 Kaplan E L, Meier P. Non-parametric estimation from incomplete observations.  J Am Stat Assoc. 1959;  33 456-481
• 38 Extra J M, Marty M, Brienza S. et al . Pharmacokinetics and safety profile of oxaliplatin.  Seminars in Oncology. 1998;  25 13-22
• 39 Lévi F, Misset J L, Brienza S. et al . A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer.  Cancer. 1992;  69 893-900
• 40 Tashiro T, Kawada Y, Sakurai Y. et al . Antitumor activity of a new platinum complex, oxalo(trans-1,2,2-diaminocyclohexane)platinum(II): New experimental data.  Biomed pharmacother. 1989;  43 251-260
• 41 Aranda E, Cervantes A, Dorta J. et al . A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).  Ann Oncol. 1998;  9 727-731
• 42 Grothey A, Deschler B, Kroening H. et al . Phase III Study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24 h5-FU infusion/ FA + Oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC).  Proc Am Soc Clin Oncol. 2002;  512
• 43 Saliba F, Hapipantelli R, Misset J L. et al . Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.  J Clin Oncol. August 1998;  16 (8) 2745-2751
• 44 Nehls O, Porschen R, Gregor M. et al . Stellenwert von Oxaliplatin in der Therapie des fortgeschrittenen kolorektalen Karzinoms.  Z Gastroenterol. 2001;  39 1033-1047
• 45 Berteault-Cvitkovic F, Jami A, Itzakhi M. et al . Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5- fluorouracil and leucovorin in patients with metastatic colorectal cancer.  J Clin Oncol. 1996;  14 2950-2958
• 46 Caussanel J P, Levi F, Brienza S. et al . Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.  Cancer. 1995;  76 559-563
• 47 Cortazar P, Johnson B E. Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer.  J Clin Oncol. 1999;  17 1625-1631